Literature DB >> 28718500

Neurofilament light as an immune target for pathogenic antibodies.

Fabiola Puentes1, Baukje J van der Star2, Stephanie D Boomkamp3, Markus Kipp4, Louis Boon5, Isabel Bosca1,6, Joel Raffel1, Sharmilee Gnanapavan1, Paul van der Valk2, Jodie Stephenson1, Susan C Barnett7, David Baker1, Sandra Amor1,2.   

Abstract

Antibodies to neuronal antigens are associated with many neurological diseases including paraneoplastic neurological disorders, epilepsy, amyotrophic lateral sclerosis and multiple sclerosis. Immunization with neuronal antigens such as neurofilament light (NF-L), a neuronal intermediate filament in axons, has been shown to induce neurological disease and spasticity in mice. Also, although antibodies to NF-L are widely used as surrogate biomarkers of axonal injury in amyotrophic lateral sclerosis and multiple sclerosis, it remains to be elucidated if antibodies to NF-L contribute to neurodegeneration and neurological disease. To address this, we examined the pathogenic role of antibodies directed to NF-L in vitro using spinal cord co-cultures and in vivo in experimental autoimmune encephalomyelitis (EAE) and optic neuritis animal models of multiple sclerosis. Here we show that peripheral injections of antibodies to NF-L augmented clinical signs of neurological disease in acute EAE, increased retinal ganglion cell loss in experimental optic neuritis and induced neurological signs following intracerebral injection into control mice. The pathogenicity of antibodies to NF-L was also observed in spinal cord co-cultures where axonal loss was induced. Taken together, our results reveal that as well as acting as reliable biomarkers of neuronal damage, antibodies to NF-L exacerbate neurological disease, suggesting that antibodies to NF-L generated during disease may also be pathogenic and play a role in the progression of neurodegeneration.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  antibodies; autoimmunity; axonal damage; neurodegeneration; neurofilament light

Mesh:

Substances:

Year:  2017        PMID: 28718500      PMCID: PMC5680069          DOI: 10.1111/imm.12797

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  49 in total

1.  A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease.

Authors:  B G Weinshenker; P C O'Brien; T M Petterson; J H Noseworthy; C F Lucchinetti; D W Dodick; A A Pineda; L N Stevens; M Rodriguez
Journal:  Ann Neurol       Date:  1999-12       Impact factor: 10.422

2.  The role of anti-myelin (auto)-antibodies in the phagocytosis of myelin by macrophages.

Authors:  A Van der Goes; M Kortekaas; K Hoekstra; C D Dijkstra; S Amor
Journal:  J Neuroimmunol       Date:  1999-11-01       Impact factor: 3.478

3.  Oligoclonal immunoglobulins and plasma cells in spinal fluid of patients with multiple sclerosis.

Authors:  E J Thompson; P Kaufmann; R C Shortman; P Rudge; W I McDonald
Journal:  Br Med J       Date:  1979-01-06

4.  Neuronal Fc-gamma receptor I mediated excitatory effects of IgG immune complex on rat dorsal root ganglion neurons.

Authors:  Lintao Qu; Pu Zhang; Robert H LaMotte; Chao Ma
Journal:  Brain Behav Immun       Date:  2011-04-18       Impact factor: 7.217

5.  Myelin-specific T cells also recognize neuronal autoantigen in a transgenic mouse model of multiple sclerosis.

Authors:  Gurumoorthy Krishnamoorthy; Amit Saxena; Lennart T Mars; Helena S Domingues; Reinhard Mentele; Avraham Ben-Nun; Hans Lassmann; Klaus Dornmair; Florian C Kurschus; Roland S Liblau; Hartmut Wekerle
Journal:  Nat Med       Date:  2009-06       Impact factor: 53.440

6.  Multiple sclerosis.

Authors:  Alastair Compston; Alasdair Coles
Journal:  Lancet       Date:  2008-10-25       Impact factor: 79.321

7.  Practical guide to the induction of relapsing progressive experimental autoimmune encephalomyelitis in the Biozzi ABH mouse.

Authors:  Sarah Al-Izki; Gareth Pryce; Janet K O'Neill; Colin Butter; Gavin Giovannoni; Sandra Amor; David Baker
Journal:  Mult Scler Relat Disord       Date:  2011-09-15       Impact factor: 4.339

8.  The development of a rat in vitro model of spinal cord injury demonstrating the additive effects of Rho and ROCK inhibitors on neurite outgrowth and myelination.

Authors:  Stephanie D Boomkamp; Mathis O Riehle; Jenifer Wood; Michael F Olson; Susan C Barnett
Journal:  Glia       Date:  2011-12-02       Impact factor: 7.452

9.  The relation between inflammation and neurodegeneration in multiple sclerosis brains.

Authors:  Josa M Frischer; Stephan Bramow; Assunta Dal-Bianco; Claudia F Lucchinetti; Helmut Rauschka; Manfred Schmidbauer; Henning Laursen; Per Soelberg Sorensen; Hans Lassmann
Journal:  Brain       Date:  2009-03-31       Impact factor: 13.501

10.  Neuroprotection in a novel mouse model of multiple sclerosis.

Authors:  Katie Lidster; Samuel J Jackson; Zubair Ahmed; Peter Munro; Pete Coffey; Gavin Giovannoni; Mark D Baker; David Baker
Journal:  PLoS One       Date:  2013-11-04       Impact factor: 3.240

View more
  4 in total

Review 1.  Pathogenic autoantibodies in multiple sclerosis - from a simple idea to a complex concept.

Authors:  Romana Höftberger; Hans Lassmann; Thomas Berger; Markus Reindl
Journal:  Nat Rev Neurol       Date:  2022-08-15       Impact factor: 44.711

2.  Plasma levels of S100B and neurofilament light chain protein in stress-related mental disorders.

Authors:  Johanna Wallensten; Fariborz Mobarrez; Marie Åsberg; Kristian Borg; Aniella Beser; Alexander Wilczek; Anna Nager
Journal:  Sci Rep       Date:  2022-05-18       Impact factor: 4.996

3.  Antibodies to neurofilament light as potential biomarkers in multiple sclerosis.

Authors:  Fabiola Puentes; Pascal Benkert; Sandra Amor; Jens Kuhle; Gavin Giovannoni
Journal:  BMJ Neurol Open       Date:  2021-11-11

4.  Humoral response to neurofilaments and dipeptide repeats in ALS progression.

Authors:  Fabiola Puentes; Vittoria Lombardi; Ching-Hua Lu; Ozlem Yildiz; Pietro Fratta; Adrian Isaacs; Yoana Bobeva; Joanne Wuu; Michael Benatar; Andrea Malaspina
Journal:  Ann Clin Transl Neurol       Date:  2021-07-27       Impact factor: 4.511

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.